This trial demonstrated that treatment with c‐Met‐CAR T cells was well‐tolerated by patients and elicited extensive tumour necrosis and was observed at the injection site inflammatory response within tumours, with no evidence of side effects greater than grade 1. This evidence concerns the gene MET and neoplasm.